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Abstract
1H Fast Field Cycling NMR (FFC‐NMR) relaxometry is proposed as a powerful
method to investigate tumour stroma in vivo upon the administration of a Gd‐
based contrast agent. To perform this study, an FFC‐NMR equipment endowed
with a wide bore magnet was used for the acquisition of Nuclear Magnetic Res-
onance Dispersion profiles on healthy muscle and tumour tissue in living mice.
At magnetic field strengths < of ca. 1 MHz, the differences in the relaxation
rates of the intra and extracellular compartment become of the same order of
magnitude of the exchange rate across the cellular membranes. Under this con-
dition, the water exchange rate between the two compartments yields to a
biexponential magnetization recovery that can be analysed by fitting the exper-
imental data with the two‐Site eXchange (2SX) model. Using this model, it was
possible to obtain, for the two compartments, both relaxation properties and
water kinetic constants for water exchange across cell membranes. The method
allowed us to determine the effect of the “matrix” on the water proton relaxa-
tion times and, in turn, to get some insights of the composition of this compart-
ment, till now, largely unknown.
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1 | INTRODUCTION
Magnetic Resonance Imaging (MRI) has got a key role in
the field of oncology since few decades. Its prominent role
relies on the superb spatial and temporal resolution of the
images it can provide. The relaxation time T1, a measure of
how fast the nuclear spinmagnetization returns to its equi-
librium state after the application of a radiofrequency
pulse, is a very important source of contrast in MRI. How-
ever, at the magnetic field strength of the currently avail-
able MRI scanners, changes in tissue T1 do not appear
sensitive enough to report on some peculiar aspects of the
tumour.[1] The noninvasive differentiation between
benign and malignant lesions (in breast cancer for exam-
ple), relies on the use of Dynamic Contrast Enhancement
MRI (DCE‐MRI) protocols, based on the use of Gd‐based
contrast agents. This procedure provides important func-
tional information related to the enhanced permeability
of blood vessels in the tumour region. Diffusion‐weighted
imaging and MR spectroscopic imaging protocols have
been implemented into the clinical practice to obtain addi-
tional functional parameters that may be simultaneously
analysed in the so‐called multiparametric imaging
approach.[2] However, there is widespread opinion
that, at low magnetic field strength, the marked increase
of R1 (=1/T1) observed in biological tissues might be used
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to improve the diagnostic potential of MRI in tumour phe-
notyping.[3–5] Although examples of 1/T1 Nuclear Mag-
netic Relaxation Dispersion (NMRD) profiles[6] acquired
in the 0.01–20MHz range on fresh or thawed surgical spec-
imens were reported since the early 80s of the past cen-
tury,[7] the interpretation of these data remains almost
completely empirical due to the lack of suitable model the-
ories for their correct and exhaustive analysis. Moreover,
the use of ex vivo samples has the flaw that it cannot take
into account the dynamics of water mobility, that is a key
determinant of the NMRD profile. Fast Field Cycling
(FFC) is the only practicable way of measuring T1‐disper-
sion; it involves switching the magnetic field between dif-
ferent field strengths, during the measurement
procedure. Recently, the prognostic potential of theNMRD
analysis has been highlighted by our group, using a proto-
type FFC relaxometer endowed with a wide bore magnet
with a dedicated transmitter/receiver solenoid detection
coil placed around the mouse's leg. Water proton 1/T1
NMRDmeasured in vivo on implantedmammary tumours
showed a marked T1 elongation at low magnetic fields
(<0.2 T) with respect to healthy tissues.[8] The differences
observed in the NMRD profiles allowed the discrimination
between mammary tumours characterised by different
metastatic potential such as 4 T1, TS/A, and 168FARN
models. These differences are directly correlated to the
exchange rate of water molecules across the membrane of
the tumour cells. In fact, the observed T1 is the result of
the mixing between the relaxation rates of the intracellular
(R1in) and extracellular compartments (R1ex), being Vex and
Vin the respective volume fractions (Figure 1). Differences
in the relaxation rates of the two compartments are
inversely proportional to the magnetic field strength,
becoming of the same order of magnitude of the exchange
rate across the cellular membranes at magnetic fields of ca.
0.025 T (i.e., at the Larmor frequency of ca. 1 MHz). Under
this condition the water exchange rate between the two
compartments yields to a biexponential magnetization
recovery that can be analysed by fitting the experimental
data with the two‐Site eXchange (2SX) model.[9–14] Thus,
the measurement at magnetic fields <1 MHz allow the
exploration of water dynamics and the separation of the
intracellular contribution from the one of the extracellular
compartment. This is not possible at high magnetic fields
because the similar values of the relaxation rates in the
extra and intracellular compartments cause the occurrence
of the fast exchange regime that makes the magnetization
recovery mono‐exponential with a relaxation rate that is
an average between the values of the two compartments.
Landis and coworkers[13] showed that, at the clinical imag-
ing fields, the biexponentiality of the Mz‐curve can be
recovered if the extracellular relaxation rate R1ex is “artifi-
cially” increased by the presence of paramagnetic contrast
agents.
The aim of our work was to explore the role a para-
magnetic contrast agent (CA), for example, Gd‐HPDO3A
(ProHance®, Bracco Imaging S.p.A., Milan, Italy), may
have on the NMRD profiles acquired in vivo on murine
models. On may expect that the paramagnetic agent
may act as a reporter of the physicochemical characteris-
tics of the “matrix” that defines the extracellular compart-
ment (Figure 1). In the literature, some example of
NMRD profiles acquired after the administration of para-
magnetic agents on fresh surgical specimens,[15–17] are
reported. However, the use of ex vivo samples has the
drawback that it cannot take into account the dynamics
of the CA distribution as well as the water mobility, that
are the key determinants of the NMRD profile.
2 | MATERIALS AND METHODS
2.1 | Animal model
BALB/c mice (Envigo, Bresso, Italy) were maintained
under specific pathogen free conditions in the animal
facility of the Molecular Biotechnology Center, University
of Turin and treated in accordance with the EU guide-
lines (EU2010/63).
Six‐week‐old female BALB/c mice were inoculated in
their muscle hind limb with about 1 million of 4 T1
(Group 1, n = 4) or TS/A (Group 2, n = 4) tumour cells
suspended in 100 μl of phosphate‐buffered saline. A third
group of untreated mice (n = 6) was used as control. Both
cell lines were initially derived from a spontaneous breast
tumour growing in a BALB/c mouse. 4 T1 (ATCC® CRL‐
2539™ purchased from American Type Culture Collec-
tion [ATCC, USA]) and TS/A (kindly provided by prof.
F. Cavallo's group, University of Turin) were grown in
RPMI 1640 medium supplemented with 10% fetal bovine
serum, 100 U/ml Penicillin (P) with 100 μg/ml
FIGURE 1 Schematic representation showing the extracellular
distribution of ProHance (green circle) in the tissue. Water
molecules reside inside the cells (Vin and R1in) and in the
extracellular space (Vex and R1ex)
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Streptomycin (S) and 4 mM Glutamine (Gln). Cells were
cultured in 5% CO2/95% air at 37°C in a humidified
chamber and were split every 2 to 3 days. All cells were
tested negative for mycoplasma by MycoAlert™ Myco-
plasma Detection Kit. All materials were purchased from
Lonza (Basel, Switzerland).
Before undergo to NMR experiments, mice were anaes-
thetized with a mixture of tiletamine/zolazepam (Zoletil
100; Vibac, Milan, Italy) 20 mg/kg and xylazine (Rompun;
Bayer, Milan, Italy) 5 mg/kg.
When tumours reached 10 mm mean diameter, mice
were euthanized for ethical reasons.
2.2 | MRI
T1‐weighted images of the mouse limb region were
acquired on a 7 T Bruker AV300 spectrometer equipped
with a Micro 2.5 microimaging probe and a birdcage
resonator with 30‐mm inner diameter. The animals
were anesthetised before MRI examination as described
above. Images were recorded 1 day before the acquisi-
tion of the NMRD profiles, before and after the injec-
tion of ProHance (0.2 mmol/Kg). The distribution of
ProHance in the tumour region was followed by
measuring T1 before and 7′, 13′, 20, 32′ after the
contrast agent injection, by means of a saturation
recovery sequence (TE = 3.3 ms; number of slices = 3;
slice thickness = 2 mm; FOV 30 × 30 mm; matrix
32 × 32). The tumour volume was measured from T2‐
weithed MRI images obtained by using a rapid acquisi-
tion with refocused echoes sequence protocol
(TR = 5,000 ms; TE = 28 ms; number of slices = 11;
slice thickness = 1 mm; FOV 50 × 50 mm; matrix
168 × 160).
Assuming the occurrence of a fast exchange regime
(i.e.,|R1in − R1ex|« kin + kex),
[18] at 7 T, the effective
intratumour ProHance concentration, [Gd]eff, was deter-
mined by Equation 1
Gd½ eff ¼ R1POST–R1PREð Þ=r1: (1)
Where R1POST and R1PRE are the relaxation rates
measured after and before the CA injection; r1 is the
millimolar relaxivity measured at 7 T of ProHance for
a 1‐mM solution in Matrigel (r1 = 4.86 mM
−1 s−1) used
as extracellular matrix model. Matrigel is the trade
name for a gelatinous protein mixture secreted by
Engelbreth‐Holm‐Swarm mouse sarcoma cells produced
and marketed by Corning Life Sciences and BD
Biosciences.
The [Gd]eff is the effective value of the tissue concen-
tration, as it refers to the sum of the intracellular and
extracellular volumes. Then, the ProHance concentration
in the extracellular volume fraction (Vex) is given by
Equation 2
Gd½ ex ¼ Gd½ eff=Vex: (2)
2.3 | NMRD profile acquisition protocol
1/T1 NMRD profiles of tumour bearing mouse (six points
at 0.01, 0.025, 0.063, 0.158, 0.398, and 1 MHz) were
acquired 10 days after cell inoculation on a Stelar SPIN-
MASTER FFC NMR relaxometer (Stelar S.n.c., Mede
[PV], Italy) equipped with a 40‐mm 0.5‐T FC magnet
and a dedicated 11‐mm solenoid detection coil. Data were
acquired with a prepolarized sequence applied at 13 MHz
and detection at 14.5 MHz, a field switching time of 4 ms,
a 90° pulse length of 5.5 μs, and 32 incremented relaxa-
tion delay (logarithmic distributed from 0.01 to 2.8 s).
The relaxometer operates under complete computer con-
trol with an absolute uncertainty in the 1/T1 value of
±2%.
The profiles were acquired pre and post the injection
of 0.2 mmol/Kg dose of ProHance.
The magnetization recovery data were analysed
according to a mono‐exponential decay (Bloch equation)
and the two‐Site eXchange model (2SX model, see below)
with Origin software (OriginPro 8.5.0 SR1, OriginLab,
Northampton, MA, Levenberg–Marquardt algorithm).
3 | RESULTS AND DISCUSSION
The two‐Site eXchange (2SX) model describes the time
evolution of MZ that depends on the absolute values of
the relative size of the “relaxation” term, |R1in − R1ex|,
and of the “exchange” term kin + kex, (where kin = 1/τin
is the water exchange rate from the extracellular to the
intracellular compartment and kex = 1/τex is the water
exchange rate in the opposite direction). This relationship
was previously defined as the NMR “shutter‐
speed.”[9,12,13] It is important to note that both R1in and
R1ex depend on the magnetic field strength; their values
are very similar at high magnetic field strength and pro-
gressively diverge on going to low magnetic field
strengths, where R1in > R1ex.
[8] R1ex is influenced by the
CA extravasation from blood capillaries to the extracellu-
lar space,[19] yielding R1ex = R1ex
0 + r1[Gd]ex, where R1ex
0
is the contribution in the absence of exchange and CA
and r1 and [Gd]ex are the extracellular CA relaxivity and
millimolar concentration, respectively. The values of the
rate constants, kin and kex, depend mainly on tempera-
ture, osmotic pressure, and cell metabolism.
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In the range 0.01–1 MHz, that represents the proton
Larmor frequencies at which the NMRD profiles were
acquired, the predominant contribution arises from
R1in, and the condition │R1in − R1ex│ ~ kin + kex is
expected to be met, even in the presence of ProHance
(that causes the increase of R1ex). The system is in an
intermediate‐exchange regime, and the longitudinal
1H2O relaxation exhibits a biexponential experimental
decay associated to two apparent contributions, one
with the larger and one with the smaller longitudinal
relaxation time. By the 2SX analysis of the Mz evolution,
it is possible to dissect the two contributions and assess
the ProHance r1 value for the extracellular compart-
ment. This method gives the possibility, for the first
time, to explore the tumour extracellular matrix that
regulates tumour cell migration and invasion, through
the detection of the r1. This parameter is a good
reporter of the interactions the paramagnetic complex
may have with the biomolecules of the microenviron-
ment in which it distributes.
Thereafter, two mouse mammary adenocarcinoma
cell lines, namely, TS/A and 4 T1, were injected in the
muscle of the hind limb to obtain the corresponding
tumour xenografts suitable for in vivo studies. In order
to set‐up the in vivo acquisition time interval of the
NMRD profiles, ProHance was administered intrave-
nously to mice bearing tumours with a volume that is
>65% of the total leg + tumour tissue. The CA
biodistribution dynamics were evaluated by measuring
T1 on a 7‐T MRI scanner after the injection of ProHance
at 0.2 mmol/kg dose. The experiment was carried out
the day before the NMRD profile acquisition in order
to deal with similar anatomical/functional conditions.
The use of a high magnetic field strength ensured the
occurrence of a fast exchange regime, that is, |
R1in − R1ex|« kin + kex, that makes the relaxation rate
measurement independent on the presence of intra
and extracellular compartments.
Figure 2 shows that the Gd concentrations ([Gd]eff)
found in both mammary tumour xenografts were signifi-
cantly higher than those found in the healthy muscle.
This is due to an increase of permeability of the neo‐
formed vessels, often called enhanced permeation and
retention, effect shown by many tumour types. By
analysing the contrast dynamic behavior, the appropriate
NMRD acquisition interval was set between 7 and 20 min
after the ProHance injection (i.e., an acquisition time of
13 min, the grey area in Figure 2). During this time, the
Gd complex concentration showed a variation of less than
30% in the tumour tissue (more precisely between
0.136 ± 0.018 mM and 0.123 ± 0.017 mM for 4 T1;
between 0.140 ± 0.009 mM and 0.115 ± 0.006 mM for
TS/A). The fast elimination of ProHance from the tumour
tissue forced us to measure R1 at a maximum of six mag-
netic field strengths, in the 0.01–1 MHz proton Larmor
frequency range.
Figure 3 shows the observed relaxation rate R1 values
obtained by the monoexponential fitting of magnetization
recovery for 4 T1 (on the left) and TS/A (on the right)
tumours before and after the injection of ProHance. As
expected, the relaxation rate measured after ProHance
injection is higher than the PRE contrast value at any
magnetic field strength. The enhancement of the relaxa-
tion rate (i.e., [R1POST‐R1PRE]/R1PRE) brought by
ProHance markedly decreases as the applied magnetic
field strength decreases. Basically, this is the consequence
of the simultaneous increase of tissue relaxation rates
(mainly due to the R1in contribution as shown above)
and the nearly constant ProHance relaxivity in this mag-
netic field range (Figure 4). A good model for the deter-
mination of T1 in the presence of ProHance in the
extracellular matrix is obtained by dissolving the CA in
Matrigel, a gelatinous protein mixture secreted by
Engelbreth–Holm–Swarm mouse sarcoma cells. It is a
model of the extracellular environment found in many
tissues and used as a substrate for cell cultures.[20]
Figure 4 shows the NMRD profile of ProHance dis-
solved in water and in Matrigel, and Table 1 reports the
parameters obtained by the fitting for the inner‐ and
outer‐sphere contributions (Solomon‐Bloembergen‐Mor-
gan and Hwang‐Freed theory,[23,24] respectively). An
increase of the rotational correlation time, τR, value of
about 60% accounts for the different behavior, as a conse-
quence of the higher viscosity of Matrigel. For both
FIGURE 2 Estimated Gd‐complex concentration in the 4 T1
(filled circle) and TS/a (filled diamond) tumour tissues and control
legs (filled square) as a function of the time after i.V.
administration. Concentration was estimated by T1 measured at 7 T
using Equation 1. The grey area indicates the time required for the
Nuclear Magnetic Relaxation Dispersion profile acquisition
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profiles, the considered τM is the value determined in
water. τM was not determined in Matrigel as this medium
changes the physicochemical state from gel to liquid at
T < 22C°. However, being τM determined by the enthalpy
of the Gd‐Ow bound, one can reasonably assume that it is
not significantly affected on going from neat water to
Matrigel.[25,26]
Next, the fitting of the magnetization recovery curves
acquired as a function of the magnetic field strength on
the two tumour models before the ProHance injection,
was then performed according to the 2SX model taking
into account the biexponential behavior of the magnetiza-
tion. Data were simultaneously analysed, sharing the Vex
end τin parameters maintaining R1ex
0 fixed to the Matrigel
values obtained in a separated experiment (Figure 4). The
Vex was allowed to vary within a reasonable range, in
accordance with results already reported in the literature
(0.09–0.19 for healthy mouse hind limb, 0.15–0.5 for
tumour mouse hind limb.[13,27–29] The R1in admitted
range was the one that previously reported on the same
type of tumours.[8] The results obtained from the
analysed NMRD profiles (six field values and 32 tau) on
healthy mouse and tumour bearing one were comparable
with those ones reported in our previous studies under
slightly different conditions (10 field values and 48 tau,
total time 32 min).[8] As expected, the tumour extracellu-
lar volume (Vex) was higher than in healthy tissue, going
from 0.13 ± 0.02 to 0.22 ± 0.01 and 0.26 ± 0.03 for
healthy, TS/A, and 4 T1 tissues, respectively.[13,27–29]
The opposite trend for the intracellular water residence
time was confirmed (1.24 ± 0.1 s for healthy tissue,
1.12 ± 0.14 s for TS/A tumour model and 0.68 ± 0.16 s
for the more aggressive 4 T1 tumour model).
In principle, the fitting of the NMRD data acquired
after the ProHance injection involves a high number
FIGURE 4 Nuclear Magnetic Relaxation Dispersion profile of
ProHance in water (filled circle) and in Matrigel (filled square),
referred to the left y‐axis (25°C). The Matrigel contribution is also
reported (open square), referred to the right y‐axis
TABLE 1 Parameters obtained by the fitting procedure of the
Nuclear Magnetic Relaxation Dispersion experimental data (25°C)
Water Matrigel
Δ2 (1019 s−2) 4.6 ± 1 6.2 ± 0.6
τv (ps) 15 ± 2 15 ± 1




D (cm2 s−1) 2.25e−5* 2.0e−5b.*
a (Å) 3.8*
aThe considered τM is the average value determined in water weighted over
the relative isomeric population the ratio for the two possible coordination
geometries SAP (capped square antiprismatic geometry) and TSAP (capped
twisted square antiprismatic geometry) is 75% and 25%, respectively[21,22];
bthe value was fixed taking into account the relative differences (14%) of the
apparent diffusion coefficient measured by DWI‐MRI (see supplementary
material) in water and in Matrigel, respectively.
*Fixed during the fitting procedure.
FIGURE 3 Nuclear Magnetic Relaxation Dispersion profile of tumour bearing (4 T1 on the left and TS/A on the right) mouse leg before
(pre, open symbol) and after (post, filled symbol) the injection of ProHance. The number of animal tested was at least 4. Error bars report the
standard deviation. During the saturation recovery acquisition, 32 tau values were spaced logarithmically from 7 m s to 2.8 s
BARONI ET AL. 849
(n = 6) of unknown parameters (R1in, R1ex, τin, Vex, [Gd]ex,
r1 of the Gd‐complex in the extracellular space of the tis-
sue). Thus, for each mouse, the fitting was carried out by
fixing: R1in, Vex, and τin, at the values found in the analy-
sis of the corresponding PRE‐contrast NMRD profiles.
The [Gd]ex concentration value was the one from the
contrasted images acquired at 7 T (Figure 2) assuming
that the Gd‐complex distribution is exclusively extra cel-
lular (Vex) and taking into account, the [Gd] decrease in
the time interval (see Equations 1 and 2). The resulting
R1in and R1ex obtained applying this fitting protocol are
reported in Figure 5. The slight increase of R1ex observed
at ca. 1 MHz may be due to that, in the 2SX model, the
compartment with lower R1 is no longer the extracellular
one as a consequence of the decrease of the intracellular
relaxation rate. This can cause a slight error in the R1ex
estimation. The r1 values obtained from the fitting
(Figure 6), referred to the extracellular compartment,
are reasonably similar to those one obtained for
ProHance in Matrigel. This is the first time that an
NMRD profile of a paramagnetic contrast agent is
obtained in vivo after its distribution in the extracellular
matrix of mammary tumour, taking into account the
water exchange rate with the intracellular compartment.
This finding gives further support to the view that the
extracellular matrix in these type of tumours shows a
slightly increased viscosity that, however, does not cause
any dramatic change in the ProHance r1. This could be
due to the presence of a limited amount of proteins or
other polymeric species (the “matrix”) in these aggressive
and partially necrotic tumours. In fact, the mobility of
water appears similar to the one shown in a gel‐like
matrix as Matrigel that can be definitively considered a
good model for the extracellular matrix in this kind of
tumours. Finally, in the presence of clinical doses of
Gd‐CA, the magnetization recovery, in the investigated
magnetic field strength range, can be well described by
the 2SX model.
4 | CONCLUSION
Herein the first in vivo NMRD profiles for tumour tissues,
obtained in the presence of a paramagnetic Gd‐complex
are reported. Upon the analysis of the experimental data
obtained in the 0.01–1 MHz range by means of the 2SX
procedure before the CA injection, it has been possible
to extract the relaxation rate values for the extracellular
and intracellular compartment (R1ex
0 and R1in), the intra-
cellular water residence time (τin) and the intracellular
water fraction (Vin = 1‐Vex). Fixing these values, it was
then possible to extract the r1 relaxivity of the paramag-
netic agent in the extracellular compartment where it dis-
tributes. The obtained values are similar to those
obtained when ProHance is dissolved in Matrigel that,
therefore, results to be an excellent model to mimic the
FIGURE 5 The relaxation rate contributions of the intracellular (filled square) and extracellular spaces (open square) obtained by
analysing the Mz recovery curve acquired as a function of the magnetic field strength according to the 2SX model, as described in the text
FIGURE 6 Relaxivity of ProHance dissolved in Matrigel (filled
square) in comparison with the value obtained from the data
fitting of tumour bearing mouse model (filled circle)
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characteristics of the extracellular compartment of the
mammary tumours considered in this work.
The method, by assessing the relaxation properties of
the extracellular space, will allow us to determine the
effect of the “matrix” on the water proton relaxation
times and, in turn, to get some insights of the composi-
tion of this compartment, till now, largely unknown. This
open new horizon in the use of the fast field cycling MRI
technologies that are currently under development for
clinical use.[30,31]
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